Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 295

1.

Knee joint distraction in regular care for treatment of knee osteoarthritis: A comparison with clinical trial data.

Jansen MP, Mastbergen SC, van Heerwaarden RJ, Spruijt S, van Empelen MD, Kester EC, Lafeber FPJG, Custers RJH.

PLoS One. 2020 Jan 22;15(1):e0227975. doi: 10.1371/journal.pone.0227975. eCollection 2020.

2.

The molecular profile of synovial fluid changes upon joint distraction and is associated with clinical response in knee osteoarthritis.

Watt FE, Hamid B, Garriga C, Judge A, Hrusecka R, Custers RJH, Jansen MP, Lafeber FP, Mastbergen SC, Vincent TL.

Osteoarthritis Cartilage. 2020 Jan 2. pii: S1063-4584(19)31301-9. doi: 10.1016/j.joca.2019.12.005. [Epub ahead of print]

3.

Sialic Acid-Engineered IL4-10 Fusion Protein is Bioactive and Rapidly Cleared from the Circulation.

Steen-Louws C, Boross P, Prado J, Meeldijk J, Langenhorst JB, Huitema ADR, den Hartog MT, Boon L, Lafeber FPJG, Hack CE, Eijkelkamp N, Popov-Celeketic J.

Pharm Res. 2019 Dec 26;37(2):17. doi: 10.1007/s11095-019-2744-y.

4.

Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.

Verhoeven MMA, Tekstra J, Welsing PMJ, Pethö-Schramm A, Borm MEA, Bruyn GAW, Bos R, Griep EN, Klaasen R, van Laar JM, Lafeber FPJG, Bijlsma JWJ, de Hair MJH, Jacobs JWG.

Rheumatology (Oxford). 2019 Dec 20. pii: kez602. doi: 10.1093/rheumatology/kez602. [Epub ahead of print]

PMID:
31859346
5.

Canine IL4-10 fusion protein provides disease modifying activity in a canine model of OA; an exploratory study.

van Helvoort EM, Popov-Celeketic J, Eijkelkamp N, Coeleveld K, Tryfonidou MA, Wijne CD, Hack CE, Lafeber FPJG, Mastbergen SC.

PLoS One. 2019 Jul 11;14(7):e0219587. doi: 10.1371/journal.pone.0219587. eCollection 2019.

6.

Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.

Verhoeven MM, de Hair MJ, Tekstra J, Bijlsma JW, van Laar JM, Pethoe-Schramm A, Borm ME, Ter Borg EJ, Linn-Rasker SP, Teitsma XM, Lafeber FP, Jacobs JW, Welsing PM.

Ann Rheum Dis. 2019 Oct;78(10):1333-1338. doi: 10.1136/annrheumdis-2019-215304. Epub 2019 Jun 13.

PMID:
31196844
7.

Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis: a Systematic Literature Review.

Verhoeven MMA, Welsing PMJ, Bijlsma JWJ, van Laar JM, Lafeber FPJG, Tekstra J, Jacobs JWG.

Curr Rheumatol Rep. 2019 Apr 23;21(6):24. doi: 10.1007/s11926-019-0821-1. Review.

8.

Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis.

Besselink NJ, Westgeest AAA, Klaasen R, Gamala M, van Woerkom JM, Tekstra J, Verhoeven MMA, Van Spil WE, Lafeber FPJG, Marijnissen ACA, Van Laar JM, Jacobs JWG.

Trials. 2019 Apr 17;20(1):226. doi: 10.1186/s13063-019-3285-8.

9.

Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review.

Roodenrijs NMT, van der Goes MC, Welsing PMJ, Tekstra J, van Laar JM, Lafeber FPJG, Bijlsma JWJ, Jacobs JWG.

Joint Bone Spine. 2020 Jan;87(1):13-23. doi: 10.1016/j.jbspin.2019.04.002. Epub 2019 Apr 11.

PMID:
30981868
10.

Can optical spectral transmission assess ultrasound-detected synovitis in hand osteoarthritis?

Besselink NJ, Jacobs JWG, Westgeest AAA, van der Meijde P, Welsing PMJ, Marijnissen ACA, Lafeber FPJG, Van Spil WE.

PLoS One. 2019 Feb 22;14(2):e0209761. doi: 10.1371/journal.pone.0209761. eCollection 2019.

11.

Knee Joint Distraction Compared with High Tibial Osteotomy and Total Knee Arthroplasty: Two-Year Clinical, Radiographic, and Biochemical Marker Outcomes of Two Randomized Controlled Trials.

Jansen MP, Besselink NJ, van Heerwaarden RJ, Custers RJH, Emans PJ, Spruijt S, Mastbergen SC, Lafeber FPJG.

Cartilage. 2019 Feb 13:1947603519828432. doi: 10.1177/1947603519828432. [Epub ahead of print]

PMID:
30758214
12.

The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.

Roodenrijs NMT, de Hair MJH, Wheater G, Elshahaly M, Tekstra J, Teng YKO, Lafeber FPJG, Hwang CC, Liu X, Sasso EH, van Laar JM.

Arthritis Res Ther. 2018 Nov 20;20(1):256. doi: 10.1186/s13075-018-1750-5.

13.

Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.

Teitsma XM, Yang W, Jacobs JWG, Pethö-Schramm A, Borm MEA, Harms AC, Hankemeier T, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Arthritis Res Ther. 2018 Oct 15;20(1):230. doi: 10.1186/s13075-018-1729-2.

14.

IL4-10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10.

Steen-Louws C, Hartgring SAY, Popov-Celeketic J, Lopes AP, de Smet MBM, Eijkelkamp N, Lafeber FPJG, Hack CE, van Roon JAG.

Clin Exp Immunol. 2019 Jan;195(1):1-9. doi: 10.1111/cei.13224. Epub 2018 Nov 11.

15.

Human C-reactive protein aggravates osteoarthritis development in mice on a high-fat diet.

Kozijn AE, Tartjiono MT, Ravipati S, van der Ham F, Barrett DA, Mastbergen SC, Korthagen NM, Lafeber FPJG, Zuurmond AM, Bobeldijk I, Weinans H, Stoop R.

Osteoarthritis Cartilage. 2019 Jan;27(1):118-128. doi: 10.1016/j.joca.2018.09.007. Epub 2018 Sep 22.

16.

Models of arthropathy: what can we learn from them to improve patient care?

Pulles AE, Lafeber FPJG, van Vulpen LFD.

Rheumatology (Oxford). 2019 Apr 1;58(4):565-566. doi: 10.1093/rheumatology/key278. No abstract available.

PMID:
30239955
17.

Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis.

Teitsma XM, Jacobs JWG, de Jong PHP, Hazes JMW, Weel AEAM, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Ann Rheum Dis. 2019 Jan;78(1):142-144. doi: 10.1136/annrheumdis-2018-213767. Epub 2018 Aug 29. No abstract available.

PMID:
30158123
18.

Initial tissue repair predicts long-term clinical success of knee joint distraction as treatment for knee osteoarthritis.

Jansen MP, van der Weiden GS, Van Roermund PM, Custers RJH, Mastbergen SC, Lafeber FPJG.

Osteoarthritis Cartilage. 2018 Dec;26(12):1604-1608. doi: 10.1016/j.joca.2018.08.004. Epub 2018 Aug 21.

19.

The combination of urinary CTX-II and serum CS-846: Promising biochemical markers to predict radiographic progression of haemophilic arthropathy-An exploratory study.

Pulles AE, Mastbergen SC, Foppen W, Schutgens REG, Lafeber FPJG, van Vulpen LFD.

Haemophilia. 2018 Jul;24(4):e278-e280. doi: 10.1111/hae.13554. Epub 2018 Jul 25. No abstract available.

PMID:
30044054
20.

Cartilage Quality (dGEMRIC Index) Following Knee Joint Distraction or High Tibial Osteotomy.

Besselink NJ, Vincken KL, Bartels LW, van Heerwaarden RJ, Concepcion AN, Marijnissen ACA, Spruijt S, Custers RJH, van der Woude JAD, Wiegant K, Welsing PMJ, Mastbergen SC, Lafeber FPJG.

Cartilage. 2020 Jan;11(1):19-31. doi: 10.1177/1947603518777578. Epub 2018 Jun 2.

PMID:
29862834
21.

RNA sequencing to predict response to TNF-α inhibitors reveals possible mechanism for nonresponse in smokers.

Cuppen BVJ, Rossato M, Fritsch-Stork RDE, Concepcion AN, Linn-Rasker SP, Bijlsma JWJ, van Laar JM, Lafeber FPJG, Radstake TR; all SRU investigators.

Expert Rev Clin Immunol. 2018 Jul;14(7):623-633. doi: 10.1080/1744666X.2018.1480937. Epub 2018 Jun 6.

PMID:
29808722
22.

IL4-10 fusion protein has chondroprotective, anti-inflammatory and potentially analgesic effects in the treatment of osteoarthritis.

Steen-Louws C, Popov-Celeketic J, Mastbergen SC, Coeleveld K, Hack CE, Eijkelkamp N, Tryfonidou M, Spruijt S, van Roon JAG, Lafeber FPJG.

Osteoarthritis Cartilage. 2018 Aug;26(8):1127-1135. doi: 10.1016/j.joca.2018.05.005. Epub 2018 May 26.

23.

Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.

Teitsma XM, Jacobs JWG, Welsing PMJ, de Jong PHP, Hazes JMW, Weel AEAM, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Ann Rheum Dis. 2018 Sep;77(9):1261-1267. doi: 10.1136/annrheumdis-2018-213035. Epub 2018 May 14.

PMID:
29760159
24.

Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics.

Teitsma XM, Jacobs JWG, Concepcion AN, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Clin Exp Rheumatol. 2018 Nov-Dec;36(6):976-983. Epub 2018 May 8.

25.

Local and systemic inflammatory lipid profiling in a rat model of osteoarthritis with metabolic dysregulation.

de Visser HM, Mastbergen SC, Ravipati S, Welsing PMJ, Pinto FC, Lafeber FPJG, Chapman V, Barrett DA, Weinans H.

PLoS One. 2018 Apr 23;13(4):e0196308. doi: 10.1371/journal.pone.0196308. eCollection 2018.

26.

Optical spectral transmission to assess inflammation in hand and wrist joints of rheumatoid arthritis patients.

Besselink NJ, van der Meijde P, Rensen WHJ, Meijer PBL, Marijnissen ACA, van Laar JM, Lafeber FPJG, Jacobs JWG.

Rheumatology (Oxford). 2018 May 1;57(5):865-872. doi: 10.1093/rheumatology/kex531.

PMID:
29471516
27.

Fib3-3 as a Biomarker for Osteoarthritis in a Rat Model with Metabolic Dysregulation.

de Visser HM, Sanchez C, Mastbergen SC, Lafeber FPJG, Henrotin YE, Weinans H.

Cartilage. 2019 Jul;10(3):329-334. doi: 10.1177/1947603518754629. Epub 2018 Jan 24.

28.

Disease burden of knee osteoarthritis patients with a joint replacement compared to matched controls: a population-based analysis of a Dutch medical claims database.

Nielen JTH, Boonen A, Dagnelie PC, van den Bemt BJF, Emans PJ, Lafeber FPJG, van Spil WE, de Vries F, Welsing PMJ.

Osteoarthritis Cartilage. 2018 Feb;26(2):202-210. doi: 10.1016/j.joca.2017.11.012. Epub 2017 Dec 2.

29.

Imaging of Folate Receptor Expressing Macrophages in the Rat Groove Model of Osteoarthritis: Using a New DOTA-Folate Conjugate.

de Visser HM, Korthagen NM, Müller C, Ramakers RM, Krijger GC, Lafeber FPJG, Beekman FJ, Mastbergen SC, Weinans H.

Cartilage. 2018 Apr;9(2):183-191. doi: 10.1177/1947603517738073. Epub 2017 Nov 3.

30.

Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2018 Feb 1;57(2):309-317. doi: 10.1093/rheumatology/kex386.

PMID:
29095992
31.

Variable cartilage degradation in mice with diet-induced metabolic dysfunction: food for thought.

Kozijn AE, Gierman LM, van der Ham F, Mulder P, Morrison MC, Kühnast S, van der Heijden RA, Stavro PM, van Koppen A, Pieterman EJ, van den Hoek AM, Kleemann R, Princen HMG, Mastbergen SC, Lafeber FPJG, Zuurmond AM, Bobeldijk I, Weinans H, Stoop R.

Osteoarthritis Cartilage. 2018 Jan;26(1):95-107. doi: 10.1016/j.joca.2017.10.010. Epub 2017 Oct 24.

32.

Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, Hendriks L, Denissen NHAM, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2017 Dec 1;56(12):2179-2189. doi: 10.1093/rheumatology/kex319.

PMID:
29029185
33.

Technical feasibility of personalized articulating knee joint distraction for treatment of tibiofemoral osteoarthritis.

Struik T, Jaspers JEN, Besselink NJ, van Roermund PM, Plomp S, Rudert MJ, Lafeber FPJG, Mastbergen SC.

Clin Biomech (Bristol, Avon). 2017 Nov;49:40-47. doi: 10.1016/j.clinbiomech.2017.08.002. Epub 2017 Aug 12.

PMID:
28865300
34.

Metabolic dysregulation accelerates injury-induced joint degeneration, driven by local inflammation; an in vivo rat study.

de Visser HM, Mastbergen SC, Kozijn AE, Coeleveld K, Pouran B, van Rijen MH, Lafeber FPJG, Weinans H.

J Orthop Res. 2018 Mar;36(3):881-890. doi: 10.1002/jor.23712. Epub 2017 Sep 20.

35.

Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.

Teitsma XM, Jacobs JWG, Mokry M, Borm MEA, Pethö-Schramm A, van Laar JM, Bijlsma JWJ, Lafeber FPJ.

Arthritis Res Ther. 2017 Jul 20;19(1):170. doi: 10.1186/s13075-017-1378-x.

36.

A fusion protein of interleukin-4 and interleukin-10 protects against blood-induced cartilage damage in vitro and in vivo.

van Vulpen LFD, Popov-Celeketic J, van Meegeren MER, Coeleveld K, van Laar JM, Hack CE, Schutgens REG, Mastbergen SC, Lafeber FPJG.

J Thromb Haemost. 2017 Sep;15(9):1788-1798. doi: 10.1111/jth.13778. Epub 2017 Aug 17.

37.

Brief Report: Induction of Matrix Metalloproteinase Expression by Synovial Wnt Signaling and Association With Disease Progression in Early Symptomatic Osteoarthritis.

van den Bosch MH, Blom AB, van de Loo FA, Koenders MI, Lafeber FP, van den Berg WB, van der Kraan PM, van Lent PL.

Arthritis Rheumatol. 2017 Oct;69(10):1978-1983. doi: 10.1002/art.40206. Epub 2017 Aug 29.

38.

Five-Year Follow-up of Knee Joint Distraction: Clinical Benefit and Cartilaginous Tissue Repair in an Open Uncontrolled Prospective Study.

van der Woude JAD, Wiegant K, van Roermund PM, Intema F, Custers RJH, Eckstein F, van Laar JM, Mastbergen SC, Lafeber FPJG.

Cartilage. 2017 Jul;8(3):263-271. doi: 10.1177/1947603516665442. Epub 2016 Aug 26.

39.

Differential effects of bleeds on the development of arthropathy - basic and applied issues.

van Vulpen LFD, Mastbergen SC, Lafeber FPJG, Schutgens REG.

Haemophilia. 2017 Jul;23(4):521-527. doi: 10.1111/hae.13236. Epub 2017 Apr 21. Review.

PMID:
28429865
40.

Automatic Quantification of Radiographic Wrist Joint Space Width of Patients With Rheumatoid Arthritis.

Huo Y, Vincken KL, van der Heijde D, de Hair MJH, Lafeber FP, Viergever MA.

IEEE Trans Biomed Eng. 2017 Nov;64(11):2695-2703. doi: 10.1109/TBME.2017.2659223.

PMID:
28141515
41.

Polymorphisms in the multidrug-resistance 1 gene related to glucocorticoid response in rheumatoid arthritis treatment.

Cuppen BV, Pardali K, Kraan MC, Marijnissen AC, Yrlid L, Olsson M, Bijlsma JW, Lafeber FP, Fritsch-Stork RD.

Rheumatol Int. 2017 Apr;37(4):531-536. doi: 10.1007/s00296-017-3653-1. Epub 2017 Jan 28.

42.

Knee joint distraction compared with total knee arthroplasty: a randomised controlled trial.

van der Woude JA, Wiegant K, van Heerwaarden RJ, Spruijt S, Emans PJ, Mastbergen SC, Lafeber FP.

Bone Joint J. 2017 Jan;99-B(1):51-58. doi: 10.1302/0301-620X.99B1.BJJ-2016-0099.R3.

PMID:
28053257
43.

Validation of automatic joint space width measurements in hand radiographs in rheumatoid arthritis.

Schenk O, Huo Y, Vincken KL, van de Laar MA, Kuper IH, Slump KC, Lafeber FP, Bernelot Moens HJ.

J Med Imaging (Bellingham). 2016 Oct;3(4):044502. Epub 2016 Nov 23.

44.

Pathophysiology of hemophilic arthropathy and potential targets for therapy.

Pulles AE, Mastbergen SC, Schutgens RE, Lafeber FP, van Vulpen LF.

Pharmacol Res. 2017 Jan;115:192-199. doi: 10.1016/j.phrs.2016.11.032. Epub 2016 Nov 24. Review.

PMID:
27890816
45.

Automated joint space width quantification of hand and wrist joints: a proof of concept study.

Huo Y, Veldhuizen RD, van der Heijde DM, Besselink NJ, Jacobs JW, van Laar JM, Viergever MA, Vincken KL, Lafeber FP, de Hair MJ; Society for Rheumatology Research Utrecht investigators.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S34-S39. Epub 2016 Oct 18.

46.

Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs.

Cuppen BV, Jacobs JW, Ter Borg EJ, Marijnissen AC, Bijlsma JW, Lafeber FP, van Laar JM; all SRU investigators.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):221-228. Epub 2016 Oct 7.

47.

Differences between serum polar lipid profiles of male and female rheumatoid arthritis patients in response to glucocorticoid treatment.

Fu J, Cuppen BV, Welsing PM, van Wietmarschen H, Harms AC, Berger R, Koval S, Fritsch-Stork RD, Bijlsma JW, Hankemeier T, van der Greef J, Lafeber FP.

Inflammopharmacology. 2016 Dec;24(6):397-402. Epub 2016 Sep 28.

48.
49.

Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis.

Cuppen BV, Fu J, van Wietmarschen HA, Harms AC, Koval S, Marijnissen AC, Peeters JJ, Bijlsma JW, Tekstra J, van Laar JM, Hankemeier T, Lafeber FP, van der Greef J; all Society for Rheumatology Research Utrecht investigators.

PLoS One. 2016 Sep 15;11(9):e0163087. doi: 10.1371/journal.pone.0163087. eCollection 2016.

50.

A potential role for glycated cross-links in abdominal aortic aneurysm disease.

Koole D, van Herwaarden JA, Schalkwijk CG, Lafeber FPJG, Vink A, Smeets MB, Pasterkamp G, Moll FL.

J Vasc Surg. 2017 May;65(5):1493-1503.e3. doi: 10.1016/j.jvs.2016.04.028. Epub 2016 Sep 10.

Supplemental Content

Loading ...
Support Center